Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

QR Code

Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. Th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu
Format:	article
Language:	EN
Published:	Nature Portfolio 2017
Subjects:	Medicine R Science Q
Online Access:	https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c09
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis
by: Lana C. Pinto, et al.
Published: (2018)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
by: Wang N, et al.
Published: (2019)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
by: Das SS, et al.
Published: (2014)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019)

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
by: Gurgel Penaforte-Saboia J, et al.
Published: (2021)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
by: Aleksander Sergeevich Ametov, et al.
Published: (2015)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
by: Chen L, et al.
Published: (2020)

Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts
by: Emilie Normand, et al.
Published: (2017)

Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
by: Suman RK, et al.
Published: (2016)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014)

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
by: Soo Lim, et al.
Published: (2012)

Dipeptidyl peptidase-IV inhibitory action of Calebin A: An in silico and in vitro analysis
by: Nehru Sai Suresh Chalichem, et al.
Published: (2021)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015)

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
by: Kornél Király, et al.
Published: (2018)

Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
by: Taehwan Park, et al.
Published: (2021)

Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality.
by: Margaret G Gall, et al.
Published: (2013)

Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
by: Sheriza Baksh, et al.
Published: (2021)

Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis
by: Yi-Chen Li, et al.
Published: (2021)

Molecular Dynamics Simulations Study of the Interactions between Human Dipeptidyl-Peptidase III and Two Substrates
by: Shitao Zhang, et al.
Published: (2021)

Gliptins vs. Milk-derived Dipeptidyl-Peptidase IV Inhibiting Biopeptides: Physicochemical Characterization and Pharmacokinetic Profiling
by: Jorge Andrés Barrero, et al.
Published: (2021)

Dipeptidyl peptidase III as a DNA marker to investigate epidemiology and taxonomy of Old World Leishmania species.
by: Insaf Bel Hadj Ali, et al.
Published: (2021)

Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes
by: Galina Smushkin, et al.
Published: (2009)

Structural basis for an exceptionally strong preference for asparagine residue at the S2 subsite of Stenotrophomonas maltophilia dipeptidyl peptidase 7
by: Akihiro Nakamura, et al.
Published: (2021)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
by: James M. Henderson, et al.
Published: (2021)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021)

Plasma dipeptidyl-peptidase-4 activity is associated with left ventricular systolic function in patients with ST-segment elevation myocardial infarction
by: Jing Wei Li, et al.
Published: (2017)

The Effect of Bioactive Polyphenols from <i>Anacardium occidentale</i> Linn. Leaves on α-Amylase and Dipeptidyl Peptidase IV Activities
by: Nur Imanina Abdullah Thaidi, et al.
Published: (2020)

Sequential alcalase and flavourzyme treatment for preparation of α-amylase, α-glucosidase, and dipeptidyl peptidase (DPP)-IV inhibitory peptides from oat protein
by: Lourdes Ramírez Fuentes, et al.
Published: (2021)

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review.
by: Martin C S Wong, et al.
Published: (2014)

Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
by: Woodman OL, et al.
Published: (2019)

Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials
by: Man Yang, et al.
Published: (2021)

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion
by: Takumi Kishimoto, et al.
Published: (2021)

Ultrasound guidance for radial artery catheterization: an updated meta-analysis of randomized controlled trials.
by: Lu Tang, et al.
Published: (2014)

Binocular treatment for amblyopia: A meta-analysis of randomized clinical trials.
by: Matilde Roda, et al.
Published: (2021)

Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials.
by: Jia Yao, et al.
Published: (2021)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Yunhai Li, et al.
Published: (2021)

The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials
by: Mateusz Socha, et al.
Published: (2019)

Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
by: Yukai Liu, et al.
Published: (2013)